Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?

References

• Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006;124(4):837-48
   PubMed Web of Science ®Google Scholar
• Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464(7285):59-65
   PubMed Web of Science ®Google Scholar
• Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA 2011;108(Suppl 1):4578-85
   PubMed Web of Science ®Google Scholar
• Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol 2007;5(7):e177
   PubMed Web of Science ®Google Scholar
• Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007;66(3):307-15
   PubMed Web of Science ®Google Scholar
• Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90(3):859-904
   PubMed Web of Science ®Google Scholar
• Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci USA 2003;100(18):10452-9
   PubMed Web of Science ®Google Scholar
• Sha S, Xu B, Wang X, et al. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis 2013;75(3):245-51
   PubMed Web of Science ®Google Scholar
• de Wouters T, Doré J, Lepage P. Does our food (environment) change our gut microbiome (‘in-vironment’): a potential role for inflammatory bowel disease? Dig Dis 2012;30(Suppl 3):33-9
   PubMedGoogle Scholar
• Hold GL, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 2014;20(5):1192-210
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007;104(34):13780-5
   PubMed Web of Science ®Google Scholar
• Sartor B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134(2):577-94
   PubMed Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014;15(3):382-92
   PubMed Web of Science ®Google Scholar
• Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012;36(6):503-16
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Gerardi V, Lopetuso LR, et al. Gut Microbial Flora, Prebiotics, and Probiotics in IBD: their Current Usage and Utility. Biomed Res Int 2013;2013:435268
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ruemmele FM, Wu GD. Nutrition, gut microbiota and immunity: therapeutic targets for IBD. Concluding remarks. Nestle Nutr Inst Workshop Ser 2014;79:161-2
   PubMedGoogle Scholar
• Kanauchi O, Iwanaga T, Mitsuyama K. Germinated barley foodstuff feeding. A novel neutraceutical therapeutic strategy for ulcerative colitis. Digestion 2001;63(Suppl 1):60-7
   PubMedGoogle Scholar
• Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut 2006;55(3):348-55
   PubMed Web of Science ®Google Scholar
• Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011;334(6052):105-8
   PubMed Web of Science ®Google Scholar
• David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505(7484):559-63
   PubMed Web of Science ®Google Scholar
• Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013;108(10):1620-30
   PubMed Web of Science ®Google Scholar
• De La Cochetière MF, Durand T, Lepage P, et al. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol 2005;43(11):5588-92
   PubMed Web of Science ®Google Scholar
• Brumfitt W, Franklin I, Grady D, et al. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984;26(5):757-61
   PubMed Web of Science ®Google Scholar
• Faith JJ, Guruge JL, Charbonneau M, et al. The long-term stability of the human gut microbiota. Science 2013;341(6141):1237439
   PubMed Web of Science ®Google Scholar
• Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008;6(11):e280
   PubMed Web of Science ®Google Scholar
• Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):661-73
   PubMed Web of Science ®Google Scholar
• Albenberg LG, Lewis JD, Wu GD. Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr Opin Gastroenterol 2012;28(4):314-20
   PubMed Web of Science ®Google Scholar
• Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999;28(2):255-81, vii
   PubMed Web of Science ®Google Scholar
• Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS. Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 1996;43(8):381-93
   PubMedGoogle Scholar
• Spehlmann ME, Begun AZ, Burghardt J, et al. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis 2008;14(7):968-76
   PubMed Web of Science ®Google Scholar
• Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011;106(4):563-73
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54; e42; quiz e30
   PubMed Web of Science ®Google Scholar
• Chapman-Kiddell CA, Davies PS, Gillen L, Radford-Smith GL. Role of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis 2010;16(1):137-51
   PubMed Web of Science ®Google Scholar
• Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr 2005;81(2):341-54
   PubMed Web of Science ®Google Scholar
• Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012;487(7405):104-8
   PubMed Web of Science ®Google Scholar
• De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010;107(33):14691-6
   PubMed Web of Science ®Google Scholar
• Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012;486(7402):222-7
   PubMed Web of Science ®Google Scholar
• Muegge BD, Kuczynski J, Knights D, et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011;332(6032):970-4
   PubMed Web of Science ®Google Scholar
• Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut 2006;55(Suppl 1):i36-58
   PubMedGoogle Scholar
• Day AS, Whitten KE, Lemberg DA, et al. Exclusive enteral feeding as primary therapy for Crohn’s disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol 2006;21(10):1609-14
   PubMed Web of Science ®Google Scholar
• Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010;50(Suppl 1):S1-13
   PubMed Web of Science ®Google Scholar
• Lionetti P, Callegari ML, Ferrari S, et al. Enteral nutrition and microflora in pediatric Crohn’s disease. JPEN J Parenter Enteral Nutr 2005;29(4 Suppl):S173-5; discussion S175-8, S184-8
   PubMed Web of Science ®Google Scholar
• Shiga H, Kajiura T, Shinozaki J, et al. Changes of faecal microbiota in patients with Crohn’s disease treated with an elemental diet and total parenteral nutrition. Dig Liver Dis 2012;44(9):736-42
   PubMedGoogle Scholar
• D’Argenio V, Precone V, Casaburi G, et al. An altered gut microbiome profile in a child affected by Crohn’s disease normalized after nutritional therapy. Am J Gastroenterol 2013;108(5):851-2
   PubMed Web of Science ®Google Scholar
• Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125(6):1401-12
   PubMed Web of Science ®Google Scholar
• Damaskos D, Kolios G. Probiotics and prebiotics in inflammatory bowel disease: microflora ‘on the scope’. Br J Clin Pharmacol 2008;65(4):453-67
   PubMed Web of Science ®Google Scholar
• Govers MJ, Gannon NJ, Dunshea FR, et al. Wheat bran affects the site of fermentation of resistant starch and luminal indexes related to colon cancer risk: a study in pigs. Gut 1999;45(6):840-7
   PubMed Web of Science ®Google Scholar
• Säemann MD, Böhmig GA, Osterreicher CH, et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 2000;14(15):2380-2
   PubMed Web of Science ®Google Scholar
• Kleessen B, Hartmann L, Blaut M. Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. Br J Nutr 2001;86(2):291-300
   PubMed Web of Science ®Google Scholar
• Videla S, Vilaseca J, Antolín M, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol 2001;96(5):1486-93
   PubMed Web of Science ®Google Scholar
• Hoentjen F, Welling GW, Harmsen H, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 2005;11(11):977-85
   PubMed Web of Science ®Google Scholar
• Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut 2011;60(7):923-9
   PubMed Web of Science ®Google Scholar
• Welters CF, Heineman E, Thunnissen FB, et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002;45(5):621-7
   PubMed Web of Science ®Google Scholar
• Cary VA, Boullata J. What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease? J Clin Nurs 2010;19(7-8):904-16
   PubMed Web of Science ®Google Scholar
• Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006;40(3):260-3
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(2):305-9
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124(5):1202-9
   PubMed Web of Science ®Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354(9179):635-9
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-23
   PubMed Web of Science ®Google Scholar
• Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011(12):CD007443
   PubMed Web of Science ®Google Scholar
• Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007(4):CD005573
   PubMed Web of Science ®Google Scholar
• Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol 2011;45(Suppl):S139-44
   PubMedGoogle Scholar
• Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13(8):1103-8
   PubMed Web of Science ®Google Scholar
• Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr Opin Gastroenterol 2009;25(4):329-33
   PubMed Web of Science ®Google Scholar
• Colombel JF, Lémann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’etudes therapeutiques des affections inflammatoires digestives (GETAID). Am J Gastroenterol 1999;94(3):674-8
   PubMed Web of Science ®Google Scholar
• Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med 2012;4(6):1051-6
   PubMed Web of Science ®Google Scholar
• Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2(4):378-424
   PubMed Web of Science ®Google Scholar
• Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39(6):1193-6
   PubMed Web of Science ®Google Scholar
• Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008;8:26
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Loening-Baucke V, Bengmark S, et al. Bacterial biofilm suppression with antibiotics for ulcerative and indeterminate colitis: consequences of aggressive treatment. Arch Med Res 2008;39(2):198-204
   PubMed Web of Science ®Google Scholar
• Koido S, Ohkusa T, Kajiura T, et al. Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy. PLoS One 2014;9(1):e86702
   PubMed Web of Science ®Google Scholar
• Walsh CJ, Guinane CM, O’Toole PW, et al. Beneficial modulation of the gut microbiota. FEBS Lett 2014;588(22):4120-30
   PubMed Web of Science ®Google Scholar
• Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010;26(1):17-25
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(Suppl 1):36-66
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn’s disease. Gastroenterology 2012;142(3):473-81; e4
   PubMed Web of Science ®Google Scholar
• Jigaranu AO, Nedelciuc O, Blaj A, et al. Is rifaximin effective in maintaining remission in Crohn’s disease? Dig Dis 2014;32(4):378-83
   PubMed Web of Science ®Google Scholar
• Maccaferri S, Vitali B, Klinder A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010;65(12):2556-65
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108(4):478-98; quiz 499
   PubMed Web of Science ®Google Scholar
• Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53(10):994-1002
   PubMed Web of Science ®Google Scholar
• Vindigni SM, Broussard EK, Surawicz CM. Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol 2013;7(7):615-28
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107(7):1079-87
   PubMed Web of Science ®Google Scholar
• Guo B, Harstall C, Louie T, et al. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012;35(8):865-75
   PubMed Web of Science ®Google Scholar
• Hamilton MJ, Weingarden AR, Unno T, et al. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013;4(2):125-35
   PubMedGoogle Scholar
• Sokol H, Seksik P, Furet JP. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009;15(8):1183-9
   PubMed Web of Science ®Google Scholar
• Borody TJ, Campbell J. Fecal microbiota transplantation: current status and future directions. Expert Rev Gastroenterol Hepatol 2011;5(6):653-5
   PubMed Web of Science ®Google Scholar
• Kunde S, Pham A, Bonczyk S, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013;56(6):597-601
   PubMed Web of Science ®Google Scholar
• Borody TJ, Brandt LJ, Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 2014;30(1):97-105
   PubMed Web of Science ®Google Scholar
• Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003;37(1):42-7
   PubMed Web of Science ®Google Scholar
• Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486(7402):207-14
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105(43):16731-6
   PubMed Web of Science ®Google Scholar
• Sokol H. Probiotics and Antibiotics in IBD. Dig Dis 2014;32(Suppl 1):10-17
   PubMedGoogle Scholar
• Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289(5483):1352-5
   PubMed Web of Science ®Google Scholar
• Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011;332(6032):974-7
   PubMed Web of Science ®Google Scholar
• Damman CJ, Miller SI, Surawicz CM, et al. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 2012;107(10):1452-9
   PubMed Web of Science ®Google Scholar